Journal article

A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIX™ adjuvant.

Ian D Davis, Juliet Quirk, Leone Morris, Lauren Seddon, Tsin Yee Tai, Genevieve Whitty, Tina Cavicchiolo, Lisa Ebert, Heather Jackson, Judy Browning, Duncan MacGregor, Frederick Wittke, Gregor Winkels, Regina Alex, Lena Miloradovic, Eugene Maraskovsky, Weisan Chen, Jonathan Cebon

Immunotherapy | Published : 2017

Abstract

AIM: Pilot clinical trial of NY-ESO-1 (ESO) protein in ISCOMATRIX™ adjuvant pulsed onto peripheral blood dendritic cells (PBDC), to ascertain feasibility, evaluate toxicity and assess induction of ESO-specific immune responses. PATIENTS & METHODS: Eligible participants had resected cancers expressing ESO or LAGE-1 and were at high risk of relapse. PBDC were produced using CliniMACS®plus, with initial depletion of CD1c+ B cells followed by positive selection of CD1c+ PBDC. Patients received three intradermal vaccinations of ESO/IMX-pulsed PBDC at 4-week intervals. RESULTS: The process was feasible and safe. No vaccine-induced immune responses were detected. Assays of immunomodulatory cells di..

View full abstract